Udhayvir Grewal, Resident Doctor at Ochsner LSU Well being Shreveport, shared a submit on X a couple of latest article by Marco Maria Germani and colleagues:
“Largest pooled RCT evaluation (N=1,604; TRIBE2, TRIPLETE, VALENTINO, ATEZOTRIBE, PANDA, PANAMA, PARADIGM, CALGB/SWOG80405) confirms their unfavourable prognostic affect of HER2 alterations in mCRC no predictive position for biologics.
HER2 amplification/over-expression (~5%): shorter PFS (9.8 vs 12.2 mo; HR 1.31, p=.02) and OS (28.0 vs 34.9 mo; HR 1.37, p=.01), related ORR (75% vs 72%).
HER2 mutations (~2%): shorter OS (23.7 vs 34.4 mo; HR 1.56, p=.04), no differential profit from anti-EGFR or bevacizumab.
In left-sided HER2+ tumors, outcomes have been related with chemo+bevacizumab vs chemo+anti-EGFR.
Takeway:
HER2 standing is a unfavourable prognostic think about pMMR/MSS RAS/BRAF WT mCRC. It shouldn’t information the frontline selection between anti-vascular vs anti-EGFR remedy.
Does this variation apply for you?”
Title: Affect of Human Epidermal Development Issue Receptor 2 in Sufferers With Metastatic Colorectal Most cancers Handled With Chemotherapy Plus Bevacizumab or Anti-EGFRs: Exploratory Evaluation of Eight Randomized Trials
Authors: Marco Maria Germani, Beatrice Borelli, Tadayoshi Hashimoto, Yoshiaki Nakamura, Simone Oldani, Francesca Battaglin, Francesca Bergamo, Lisa Salvatore, Arndt Stahler, Carlotta Antoniotti, Kohei Shitara, Alan Venook, Eiji Oki, Kei Muro, Clara Ugolini, Junpei Soeda, Sara Lonardi, Filippo Pietrantonio, Heinz-Josef Lenz, Dominik Paul Modest, Takayuki Yoshino, Chiara Cremolini
Learn the Full Article in ASCO Publications.
Extra posts that includes Udhayvir Grewal on OncoDaily.
